Kexin Li
- Pharmaceutical Science top 2%
- Advanced Drug Delivery Systems 4
- Biomaterials top 5%
- Nanoparticle-Based Drug Delivery 5
- Immunology top 10%
- Aquaculture disease management and microbiota 6
- Immune cells in cancer 5
- Oncology top 10%
- Drug Transport and Resistance Mechanisms 4
-
- Nanoplatforms for cancer theranostics 9
-
- Pharmacological Effects of Natural Compounds 4
-
- Fatty Acid Research and Health 4
- Journals
- Angewandte Chemie International Edition (1 paper)Nature Communications (1 paper)SHILAP Revista de lepidopterología (1 paper)
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Kexin Li
72 papers receiving 1.5k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Pharmaceutical Science 161
- Biomaterials 240
- Immunology 226
- Oncology 273
- Cancer Research 131
Countries citing papers authored by Kexin Li
This map shows the geographic impact of Kexin Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kexin Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kexin Li more than expected).
Fields of papers citing papers by Kexin Li
This network shows the impact of papers produced by Kexin Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kexin Li. The network helps show where Kexin Li may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kexin Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 1 | |
| 4 | 2024 | 4 | |
| 5 | 2024 | 8 | |
| 6 | 2024 | 1 | |
| 7 | 2024 | 6 | |
| 8 | 2024 | 7 | |
| 9 | 2023 | 1 | |
| 10 | 2023 | 4 | |
| 11 | 2023 | 10 | |
| 12 | 2023 | 0 | |
| 13 | 2023 | 3 | |
| 14 | 2023 | 4 | |
| 15 | 2022 | 25 | |
| 16 | 2022 | 3 | |
| 17 | 2022 | 2 | |
| 18 | 2022 | 12 | |
| 19 | 2020 | 21 | |
| 20 | 2016 | 31 |
About Kexin Li
Kexin Li is a scholar working on Pharmaceutical Science, Immunology and Pharmacology, having authored 75 papers that have together received 1.5k indexed citations. Recurring topics across this work include Nanoplatforms for cancer theranostics (9 papers), Aquaculture disease management and microbiota (6 papers), Nanoparticle-Based Drug Delivery (5 papers), Immune cells in cancer (5 papers), Pharmacological Effects of Natural Compounds (4 papers), Fatty Acid Research and Health (4 papers), Advanced Drug Delivery Systems (4 papers) and Drug Transport and Resistance Mechanisms (4 papers). The work is most often cited by research in Pharmaceutical Science (161 citations), Biomaterials (240 citations) and Immunology (226 citations). Kexin Li has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Hongtao Zhang, Lianmei Zhao, Xiaoya Li, Dawei Chen, Xiuli Zhao, Haiyang Hu, Jing Ai, Kaiwei Wan, Jing Zhao and Shaoqin Liu. Their work appears in journals such as Angewandte Chemie International Edition, Nature Communications and SHILAP Revista de lepidopterología.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.